Anti-Pulmonary Fibrosis Compound Library

Description: Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).
Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).
Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 1676 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.
MCE Anti-Pulmonary Fibrosis Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1640 compounds supplied in 10 mM solution, 30 compounds supplied in 2 mM solution and 6 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 1676 compounds for high throughput screening (HTS) and high content screening (HCS).
• A useful tool for the discovery of anti-pulmonary fibrosis drugs.
• Target diverse, medicinally active and cell permeable.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
• More detailed compound information with structure, IC50, and other chemical & biological data.
• High purity and quality validated by NMR and LC/MS.

Formulation: A collection of 1676 anti-pulmonary fibrosis inhibitors supplied as pre-dissolved Solutions or SolidSolution:1640 compounds supplied in 10 mM solution,30 compounds supplied in 2 mM solution,6 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L125-50
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L125-50
• Green Labware: Nein
• Verpackungseinheit: 50 μl
• Mengeneinheit: STK